Merck & Co's Gefapixant Effective In Refractory Cough, But Taste Concerns Remain
Data From Phase III Studies To Be Shared With Regulators
Executive Summary
Updated results from two Merck & Co Phase III studies, COUGH-1 and COUGH-2, confirm the drug’s efficacy in reducing the frequency of refractory cough and its association with taste disturbances.
You may also be interested in...
Hiccup For Evotec As Bayer Pulls Plug On Chronic Cough Drug
With the future of eliapixant in doubt, Shinogi's sivopixant struggling and a recent FDA rejection for Merck & Co's chronic cough drug gefapixant, Bellus Health's BLU-5937 looks to have emerged as a best-in-class agent in the P2X3 space.
Keeping Track: Immunocore Wins Nod For First T-Cell Receptor Therapeutic; Veklury And Nucala Expand Settings Of Use; Merck & Co. Strikes Out In Chronic Cough
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Merck's Gefapixant CRL Dashes Hopes For Another Near-Term Growth Driver
The US FDA issued a complete response letter for the P2X3 receptor antagonist for the treatment of refractory chronic cough, requesting more efficacy data.